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Abstract: Background: The selection of assays suitable for testing the potency of clinical grade
multipotent mesenchymal stromal cell (MSC)-based products and its interpretation is a challenge
for both developers and regulators. Here, we present a bioprocess design for the production of
Wharton’s jelly (WJ)-derived MSCs and a validated immunopotency assay approved by the competent
regulatory authority for batch release together with the study of failure modes in the bioprocess
with potential impact on critical quality attributes (CQA) of the final product. Methods: The
lymphocyte proliferation assay was used for determining the immunopotency of WJ-MSCs and
validated under good manufacturing practices (GMP). Moreover, failure mode effects analysis (FMEA)
was used to identify and quantify the potential impact of different unexpected situations on the
CQA. Results: A production process based on a two-tiered cell banking strategy resulted in batches
with sufficient numbers of cells for clinical use in compliance with approved specifications including
MSC identity (expressing CD73, CD90, CD105, but not CD31, CD45, or HLA-DR). Remarkably,
all batches showed high capacity to inhibit the proliferation of activated lymphocytes. Moreover,
implementation of risk management tools led to an in-depth understanding of the manufacturing
process as well as the identification of weak points to be reinforced. Conclusions: The bioprocess
design showed here together with detailed risk management and the use of a robust method for
immunomodulation potency testing allowed for the robust production of clinical-grade WJ-MSCs
under pharmaceutical standards.
Keywords: multipotent mesenchymal stromal cell; immunomodulation; proliferation assay; cellular
therapy; cell culture; good manufacturing practice; quality by design
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1. Introduction
Cell-based medicinal products hold the promise to bring therapeutic alternatives to address
unmet medical needs [1–3]. Amongst the diverse cell types that have attracted clinical interest,
multipotent mesenchymal stromal cells (MSC) emerge as strong candidates, with several clinical
trials already completed demonstrating an excellent safety profile [4]. Nonetheless, solid data on
efficacy are jeopardized by poor translation of preclinical results that may have been interpreted
too optimistically [5,6]. In this sense, a huge effort is currently being made to define specific target
conditions that could be realistically treated with such therapies, which requires robust methods of
production and suitable potency assays directly related to the mechanism of action [7]. This is a major
challenge for both developers and regulators, since the pharmacological activity of MSCs is poorly
understood, and the choice of an appropriate potency assay needs to be agreed with the competent
regulatory authority. Potency assays are defined as the “quantitative measure of biological activity
based on the attribute of the product” according to the European Guideline on Human Cell-Based
Medicinal Products, EMEA/CHMP/410869/2006. However, mechanisms of action are complex and
not fully understood. Furthermore, other limitations such as variability in starting materials, limited
stability, and lot size also increase the difficulty in establishing adequate potency tests as well as an
accurate panel of product specifications.
In the context of MSC-based therapy for the treatment of immunological disorders, the potency
assays most commonly used are based on the determination of their in vitro immunomodulation
capacity [8]. Moreover, to further ensure the quality of medicines, we followed an approach known as
quality by design (QbD), which is welcomed by the European Medicines Agency (EMA) and allows
for the control of bioprocesses by employing statistical, analytical, and risk-management methodology.
According to quality risk management, we studied in detail potential failure risks in critical steps
involved in the production process using failure mode and effects analysis (FMEA) [9] and identified
parameters that may lead to potential out-of-specification (OOS) of any of the critical quality attributes
(CQA) of the final Wharton jelly (WJ) MSC-based product, with special attention being given to the
immunopotency assay currently used for batch release.
Here, we present a validated production process compliant with current good manufacturing
practice (GMP) that addresses both (a) the challenge of establishing a robust bioprocess design and (b)
defining appropriate quality controls (QC), which include meaningful potency assays.
2. Materials and Methods
2.1. Source Tissue, MSC Derivation, and Expansion
WJ-MSCs were derived following GMP-compliant procedures reported elsewhere [10], within the
context of a clinical trial (EudraCT No. 2015-005786-23) with appropriate donor informed consent.
Briefly, a fragment of umbilical cord tissue compliant with acceptance criteria described in Table 1 was
cut longitudinally and split open so that the two arteries and the vein could be removed by pulling
them gently. WJ was scrapped with a surgical scalpel, spread uniformly over the plastic surface of
a T-flask with re-closable lid (TPP), and incubated for 30 min at 37 ◦C. After the incubation, 10 mL
of Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Carlsbad, CA, USA) containing 2 mmol/L
glutamine was added and supplemented with 2 × 104 UI/mL penicillin (Invitrogen, New York, NY,
USA), 20 mg/mL streptomycin (Invitrogen), 120 µg/mL amphotericin B (Invitrogen), and 20% human
serum B (hSerB, Banc de Sang i Teixits, Barcelona, Spain). After 2–5 days, a washing step with saline
solution was performed, and 10 mL of fresh derivation medium was added. From this point, the
culture medium was replaced every 3–4 days. Cells were further expanded in vitro by seeding cell
culture flasks at (1–3) × 103 cell/cm2 in derivation medium. When the total number of cells reached at
least 5 × 106, they were frozen in cryovials producing the master cell bank (MCB). Further expansion
was performed after thawing for the generation of either working cell bank (WCB) or drug product
(DP) directly using expansion medium composed of DMEM containing 2 mmol/L glutamine and
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supplemented with 10% hSerB (that is, “expansion medium”). Final product (FP) was defined as the
product resulting from thawing a DP, washed and conditioned for administration in patients, which
complies with criteria presented in Table 2. All cultures were maintained at 37 ◦C and 5% CO2 in
humidified incubators. Media were replaced every 3–4 days, and trypsinization was performed at
70–90% confluence.
Table 1. Acceptance criteria of starting material.
Sample Requirement Informative
Maternal Blood Negative for: HBsAb, HIV I/II, syphilis (TPPA),
Chagas, HBcAb, HCV, anti-HTLV I/II, NAT
(HCV-HIV, HBV), anti-Toxo IgM, anti-EBV VCA
IgM, anti-CMV IgM
Anti-Toxo IgG, anti- EBV VCA
IgG, anti-CMV IgG
Cord Blood HBsAb, HIV I/II, syphilis (TPPA), Chagas, HBcAb,
HCV, anti-HTLV I/II, NAT (HCV-HIV, HBV)
N/A
Umbilical Cord
Fragment ≥7 g, ≤ 80 h from birth N/A
NAT: Nucleic acids test; HIV: Human immunodeficiency virus; CMV: Cytomegalovirus; EBV: Epstein–Barr virus;
HBV: Hepatitis B virus; HCV: Hepatitis C virus; TPPA: Treponema pallidum particle agglutination assay; Toxo IgM:
Toxoplasma immunoglobulin M; HBcAb: Hepatitis B core antibody; HBsAb: Hepatitis B surface antibody; HTLV:
human T-cell leukemia–lymphoma virus; VCA: Viral capsid antibody.
Table 2. Release criteria for drug product.
Critical Quality Attribute Value
Dose 1 × 107 ± 20%
Viability ≥70%
Phenotype
CD45-/CD105+ ≥ 95%
CD31-/CD73+ ≥ 95%
CD90+ ≥ 95%
HLA-DR 1
Sterility Sterile
Mycoplasma Negative
Endotoxin ≤1EU/mL
Adventitious Viruses Negative
Immunomodulation Positive
1 HLA-DR for informative purposes only.
2.2. Flow Cytometry
Cells were numbered using Perfect-Count MicrospheresTM (Cytognos, Salamanca, Spain)
microbeads in a FACSCalibur cytometer (Becton Dickinson, San Jose, CA, USA). Viability was
determined using the 7-Amino-Actinomycin D (7-AAD, BD Biosciences, San Jose, CA, USA) exclusion
method. Data were analyzed with CellQuest Pro (Becton Dickinson) software. In accordance with the
ISCT criteria [11], mesenchymal identity was evaluated by the expression of surface markers CD31
(clone WM59; BD Biosciences), CD45 (clone HI30; BD Biosciences), CD73 (clone AD2; BD Biosciences),
CD90 (clone F15-42-1-5; Beckman Coulter Inc, Miami, FL, USA), CD105 (clone 43A4E1; Miltenyi Biotec,
Bergish Gladbach, Germany), and HLA-DR (clone L243; BD Biosciences) in a FACSCalibur device.
PE- and FITC-conjugated IgG1k (G18-145, BD Biosciences) antibodies were used as isotype controls.
Cells were stained for 15 min at room temperature, washed, and resuspended with PBS (Invitrogen).
Acquisition was done using a FACSCalibur, and data were analyzed with CellQuest Pro software
(version 5.2.1, BD Biosciences).
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2.3. Lymphocyte Proliferation Assays
The immunomodulation potential of WJ-MSCs was determined by their capacity to inhibit
the proliferation of polyclonally stimulated lymphocytes in vitro, as comprehensively described
elsewhere [12]. MNC were obtained by density gradient (Histopaque-1077; Sigma-Aldrich, Saint Louis,
MO, USA) from 24- to 48-hour-old buffy-coats or peripheral blood of healthy blood donors, which were
confirmed negative for hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency
virus (HIV), and syphilis, both by serology and viral nucleic acid detection (NAD). Next, 2.5 × 106
MNC/mL were labelled with 0.625 µM carboxy–fluorescein diacetate succinimidyl ester (CFSE) for
10 min using the CellTrace™ CFSE Cell Proliferation Kit (Molecular Probes, Eugene, OR, USA). After
washing, (1–2) × 107 cells/mL were incubated for 12 min at 37 ◦C, washed again and seeded onto
flat-bottomed 96-well plates (Corning, Corning, NY, USA) at an MNC:WJ-MSC 5:1 ratio. Activation
of lymphocytes was done with 25 ng/mL Phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich)
and 0.5 µM Ionomycin (Sigma-Aldrich) in a final volume of 0.5 mL/well of “expansion medium”.
Proliferation of MNC was determined by measuring the reduction of fluorescence intensity at day
5 using flow cytometry (FACSCalibur, Becton Dickinson), and data were analyzed with the FlowJo
software (TreeStar Inc., Ashland, OR, USA).
2.4. Karyotype
Metaphase chromosome spreads (≥20 per sample) were prepared from each cell line in the
exponential phase of growth as reported elsewhere [13]. Briefly, 25 µL of colcemid (Life Technologies,
Carlsbad, CA, USA) were added to the cultures before trypsinization for arresting the cells in metaphase.
After trypsinization, cells were fixed with Carnoy. Wrigth’s stain was used to stain chromosomes.
Then, metaphase spreads were captured and karyotyped using an automated imaging system for
cytogenetics (Cytovision, Applied Imaging, Sunderland, UK).
2.5. Risk Analysis
Quality risk management, defined by the World Health Organization (WHO) as a systematic
process for the assessment, control, communication and review of risks to the quality of the medicinal
product, was performed here in accordance with the recommendations of the International Council
for Harmonization (ICH) guideline Q9 on Quality Risk Management and WHO Good manufacturing
practices for pharmaceutical products Annex 2 guidelines. Two different steps were followed:
2.5.1. Risk Assessment
Risk assessment involved identification, analysis of probability and severity, and evaluation of
the level and need to mitigate potential risks (Table 3). After risk identification, the quantification
of the potential risks was done by performing a failure mode effect analysis (FMEA) [9,14]. This is
a quantitative tool permitting to evaluate potential risk situations, causes, and consequences, and
the evaluation of suitable corrective actions by means of the risk priority number (RPN) that takes
into consideration the occurrence of the potential risk, the possible severity, and the probability of
detecting the failure (Equation (1)). Along the risk evaluation, the severity effects and the likelihood of
the occurrence were assigned to a score from 1 to 5 (Tables S1 and S2). The likelihood that potential
failure modes are detected before altering the product quality was rated by detection values (Table S3).
Failure groups are listed in (Table S4).
RPN = Severity×Occurence×Detection (1)
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Table 3. Risk analysis.
Critical Quality Attribute Potential Failure Risk
Dose
Seeding density lower than the critical minimum
Cell viability lower than 70%
Slow cell growth
Cell loss along the manufacturing process
(washing and concentration steps)
Impurities
Contamination of the culture
Endotoxins out of range
Positive result for virus adventitious
Identity Phenotype markers out of range
Karyotype alteration
Potency Failure in the immunomodulation test
2.5.2. Risk Control
Risk control involved risk reduction or risk acceptance. Internally, RPN was classified in three
grades, low (RPN < 20), medium (RPN 20–55), and high (RPN > 55) vulnerability. Corrective
actions were implemented for those failures with an RPN number higher than the aim to minimize
the occurrence and/or enhance its detectability. Risk evaluation was carried out again after
corrective actions.
2.5.3. Graphical Representation
Provided that it is unlikely to perform all tests resulting from the FMEA, we suggest plotting a
Pareto’s chart with the objective of identifying the risks that account for 80% of failures, which typically
arise from 20% of the sources of risk [9].
2.6. Microbiological Testing
Absence of microbial contamination of MCB and WCB was verified by inoculation in iFA PLUS
and iFN PLUS media bottles (Biomerieux Industries) and incubation at 37 ◦C for 14 days. Sterility tests
of DP were conducted according to European Pharmacopea (EuPh). Anaerobic bacteria were cultured
on fluid thioglycolate medium (Biomerieux, Marcy l′Etoile, France) at 30–35 ◦C. Fungi and aerobic
bacteria were cultured on Soya-bean casein digest medium (Biomerieux) at 20–25 ◦C. Samples were
incubated for at least 14 days and then inspected visually. If no evidence of microbial growth was
found, the product was said to comply with the test for sterility. Additionally, Gram staining tests
were used for parametric release of the finished product, provided that EuPh sterility tests take two
weeks. Briefly, the test was conducted in duplicates for confirmatory purposes by overnight incubation
at 37 ◦C using three different media, namely: Columbia agar supplemented with 5% sheep blood,
Chocolate agar PolyViteX, and Sabouraud Gentamicin Chloramphenicol 2 agar (Biomerieux). If the
result was negative, then the product was considered compliant.
2.7. Endotoxin, Mycoplasm and Adventitious Virus Tests
The Endosafe-PTS system (Charles River, Wilmington, MA, USA) was used following the
manufacturer’s instructions. The Venor qEP (Minerva Biolabs, Berlin, Germany) Kit was used
for the amplification of a mycoplasma-specific 16S rRNA gene region and detection by real time
polymerase chain reaction (PCR) according to the manufacturer’s instructions. In vitro adventitious
agents’ detection in MSC samples were performed on MRC5 and Vero cells. If cytopathic effect was
observed after 14–28 days of culture, PCR and immunofluorescence techniques were used to identify
contamination agents.
Cells 2019, 8, 484 6 of 13
2.8. Statistical Analysis
Descriptive data were expressed as mean ± standard deviation (number).
3. Results
3.1. Bioprocess Design
The bioprocess design proposed here allowed for the successful isolation of MSCs from the
Wharton’s jelly harvested from umbilical cord tissue discarded after birth in maternities associated
to our blood and tissue bank. Cells were subsequently expanded in vitro up to sufficient numbers
following a GMP-compliant manufacturing process design presented in Figure 1 that involves the
establishment of cryopreserved intermediate elements (namely, MCB, WCB, and DP) to obtain a
cell-based product in a timely and cost-effective manner. The necessary steps for the establishment of
the different intermediates and the generation of the FP (Final Product) were analyzed to identify the
contamination risks, as detailed next:
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intermediate working cell bank, the competent regulatory authority allowed the possibility to expand
drug product (DP) directly from the master cell bank (MCB). UC: Umbilical cord; WJ-MSC: Wharton
jelly–mesenchymal stromal cells; IPC: In-process controls; Ph: Pharmacopea.
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before freezing.
3.1.3. Drug Product (DP)
DP was obtained following a similar procedure, in which a cryopreserved unit of WCB was
thawed and cells were expanded and frozen. After expansion, sterility tests (Bact/Alert method),
mycoplasma, and endotoxin tests were performed. Before cryopreservation, a EuPh sterility test was
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carried out. A cryopreserved DP unit was also used as control tube of the freezing–thawing process.
This tube was then thawed for testing endotoxin and adventitious virus.
3.1.4. Final Product (FP)
FP was generated by thawing two units of the DP, washing and adjustment to the final dose
concentration, and conditioning for clinical use. In this final step, the presence of endotoxins,
mycoplasma, and PhEu sterility testing was evaluated.
3.2. Identity of WJ-MSCs
Phenotypic profiling of WJ-MSCs was consistent with their mesenchymal identity, being positive
for the expression of CD73, CD90, and CD105, and negative for CD31 and CD45, and HLA-DR (Figure 2
and Table 4). Viability of FP was 97.4 ± 0.5% (n = 8) with undetectable levels of endotoxins and
mycoplasma DNA; and free of bacterial contamination and adventitious viruses in all cases. All
karyotypes were normal, with 46 chromosomes (five of which were XY, two were XX, and one could
not be determined due to low number of metaphase spreads).
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CD45−/CD105+(), 99.8 ± 0.2% CD31−/CD73+(N), 99.7 ± 0.3% CD90+ (H), 99.1 ± 0.6% HLA-DR−().
able 4. ritical quality attributes for each of the 8 batches of drug product.
1 2 3 4 5 6 7 8
Dose (×107) 2.5 2.4 2.3 2.3 2.5 2.4 2.5 2.8
Num. doses 18 6 24 14 16 20 39 41
Viability (%) 97.3 94.4 95.9 98.2 97.1 97.1 97.1 97.6
CD45−/CD105+ 99.9 99.6 100 99.6 99.9 99.9 99.9 100
CD31−/CD73+ 99.9 99.5 99.8 99.6 99.8 99.9 99.9 99.9
CD90+ 99.8 99.1 99.9 99.7 99.9 99.7 99.8 99.7
HLA-DR- 99.4 98.3 99.2 97.9 99.4 99.3 99.6 99.5
Karyotype 46X, X 46X, X n.d. 46X, Y 46X, Y 46X, Y 46X, Y 46X, Y
Sterility - - - - - - - -
Mycoplasma - - - - - - - -
Endotoxin ≤1EU/mL ≤1EU/mL ≤1EU/mL ≤1EU/mL ≤1EU/mL ≤1EU/mL ≤1EU/mL ≤1EU/mL
Adventitious viruses - - - - - - - -
Immunomodulation 87.5 89.6 83.3 83.2 61.9 97.3 84.2 100
n.d.: Not determined; -: Negative.
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3.3. Potency of WJ-MSCs
The immunopotency of cells was determined in vitro by measuring the capacity of WJ-MSCs to
inhibit the proliferation of polyclonally activated lymphocytes. In all cases, WJ-MSCs were able to
inhibit proliferation 85.9 ± 10.9% (ranging from 61.9 to 100% inhibition, n = 8; Table 4). Additionally,
microscopic pictures of stimulated PBMC were taken in the absence of WJ-MSCs (Figure 3A) when
the formation of cell aggregates was observed and when WJ-MSCs were present and the consecutive
reduction in cell clumps (Figure 3B), which correlates to immunopotency results shown in Figure 3C.
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WJ-MSC. Bright field microscopy images revealed clumping of peripheral blood MNC after 5 days in
the of presence of 25 ng/mL PMA and 0.5 µM ionomycin (A), as opposed to same cells in co-culture
with WJ-MSCs showing a dramatic decrease in the presence of such cell clumps (B). Values (in %) of
the inhibition of the proliferation of activated lymphocytes are shown in (C). Scale bars = 100 µm.
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3.4. Risk Analysis
Risk analysis of failure groups was performed and plotted with its RPN for each step of the
bioprocess, with the establishment of the MCB associated to the highest risk level regarding processes
and materials (Figure 4A). Main risks were associated with endotoxins and adventitious virus due to
two main sources: (a) Materials used and (b) open-system steps in the process. Indeed, isolation of the
umbilical cord was performed during a nonsterile process, such as birth delivery. These microbiological
parameters were not evaluated at this bank level. Importantly, while in the next steps, adventitious
virus always happened to be negative, a variability was observed in the endotoxin level across the cell
banking level. Furthermore, another high-risk level was presented by the raw material used for this
process. Therefore, it was decided to perform endotoxin testing also at the MCB level to enhance the
OOS detectability in the early process stages.
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microbiological parameters were not evaluated at this bank level. Importantly, while in the next steps, 
adventitious virus always happened to be negative, a variability was observed in the endotoxin level 
across the cell banking level. Furthermore, another high-risk level was presented by the raw material 
used for this process. Therefore, it was decided to perform endotoxin testing also at the MCB level to 
enhance the OOS detectability in the early process stages. 
 
Figure 4. Risk analysis. (A) A Pareto chart was generated and plotted according to the classification
and the failure group. (B) Graphical representation of the impact of risks from each failure group on
critical quality attributes. The graphical view of the risk analyses for each of the failure groups provided
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invaluable assistance to focus efforts in the mitigation of critical risks affecting the specifications of
MSCs in the final product. This methodology permits to streamline the identification of the weakest
points of the process that deserve the implementation of further in-process controls or to preserve
existing ones. MCB: Master cell bank; WCB: Working cell bank; DP: Drug product; FP: Final product;
RPN: Risk priority number.
Moreover, an FMEA risk analysis of the complete manufacturing process was performed, taking
into account potential risks that could impact on the critical quality attribute (CQA) (Table 3 and
Tables S5–S8). Regarding CQA of the final product, the design of the bioprocess has a major impact on
the dose and immunopotency of WJ-MSCs (Tables S5 and S8), whereas environmental factors impacted
mainly on impurities (Table S6), and reagents and materials used could mostly affect WJ-MSCs’
immunomodulation capacity (Figure 4B and Table S8). Interestingly, no high vulnerabilities were found
for failure modes in the determination of identity (Table S7). With the identification of potential risks,
measures of mitigation concluded in the reduction of RPN overall values. However, new measures of
risk mitigation can be further applied to increase risk mitigation.
4. Discussion
The interest in using MSCs for clinical applications has increased over the last few years.
To date, nearly 1000 registered clinical studies over the world have involved the use of this cell type
(www.clinicaltrials.gov; search terms: “mesenchymal” AND “stem” AND “cell”; April 2019), which
can be explained because of their unique properties, namely: Multilineage differentiation potential,
tropism to injured tissues, immunoregulatory capacity, and the release of growth factors and cytokines
in response to environmental cues [15]. Altogether, these make MSCs highly attractive for treating a
variety of diseases ranging from immune disorders to tissue regeneration [16].
Particularly, WJ-MSCs offer multiple advantages over the use of bone marrow-derived MSCs,
such as the use of non-invasive procedures for tissue collection, standardization of donor age, and lack
of somatic mutations, amongst others. Therefore, the umbilical cord emerges as an alternative source
of MSCs, involving straightforward and pain-free collection [17]. Indeed, WJ-MSCs can be extensively
expanded in culture and survive freeze/thaw cycles, thus making them suitable for the generation of cell
banks of advanced therapy medicinal products available in an off-the-shelf format [15,18]. Moreover,
WJ-MSCs have similar immunomodulation properties to BM-MSCs [19,20], which supports the use of
WJ-MSCs in graft versus host disease (GvHD) and in the treatment of other immunological disorders
along with BM-MSCs [21]. Interestingly, the use of MSCs sourced from different tissues may result in
different effects in GvHD treatments, as they hold potentially different characteristics. Indeed, Grégoire
and collaborators observed in vitro and in vivo, using a humanized mouse model, that MSCs show
different effects on immune cells according to their source [22]. Therefore, standardization of a robust
potency assay for MSCs is urgent to make possible the comparison of results from different laboratories
and ensure that in vitro functionality for GMP-manufactured products prior to administration correlates
to their clinical effect.
Although MSCs have been studied for more than 40 years, their translation into GMP-compliant
processes is far from being straightforward and requires a deep analysis of several parameters to
ensure quality, efficacy, and safety of the final product [23]. In this context, concepts of QbD offer a
systematic approach that combines scientific knowledge and risk assessment that can assist developers
and regulators in the understanding of parameters in bioprocesses that directly affect CQA of the final
product. In the last few decades, QbD has become an essential tool in the successful development
of pharmaceutical products, and consequently, regulatory organisms worldwide have adopted this
concept in their guidelines. Herein we reported the integration of risk management and bioprocess
design in the production of WJ-MSCs with immunomodulatory properties, providing main risks that
may affect the quality of the final product so the bioprocess can be improved by mitigating risks. This
approach contributes to increasing consistency and decreasing OOS.
Cells 2019, 8, 484 11 of 13
In this work, we presented the successful production of eight batches of WJ-MSC for clinical
use, all of them in compliance with GMP guidelines. Our bioprocess design received manufacturing
authorization by the competent regulatory authority, including the described potency assay based on
immunomodulation potential. Although we are aware of other methods to assess immunopotency,
it is not clear whether any of them can represent the actual mechanisms of action of the drug
substance in vivo [24]. Regulatory environments for drug manufacturing have imposed more stringent
requirements in terms of quality controls to ensure safety and efficacy throughout the life cycle
of the products. This is particularly challenging in the field of cell therapy because the active
ingredient is made of living cells, and current analytical techniques lack standardization across
laboratories [25]. We propose a sound starting point to quantify cell functionality beyond surrogate
markers of potency that is usually limited to cell viability or mesenchymal phenotype identity.
Interestingly, the quantification of the immunomodulation potential of WJ-MSCs as described here
prospectively covers a wide range of possible mechanisms of action in vivo having the paracrine mode
of action as a common characteristic. In this regard, our next objective is the evaluation of the proposed
potency assay by analyzing whether clinical results somehow correlate with the quantitative attribute
derived of the immunomodulation test.
5. Conclusions
The bioprocess design showed here and the implementation of a robust immunomodulation
potency assay has enabled us to streamline the production of clinical-grade WJ-MSCs under
pharmaceutical standards. Moreover, the application of FMEA risk management tool has provided
an in-depth fundamental understanding of the process weaknesses allowing the implementation
of the corresponding corrective actions to ensure the CQA in the final product as well as
consistency batch-to-batch.
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